Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three uterotonic agents—oxytocin, methylergonovine, and carboprost—used in the management of postpartum hemorrhage (PPH) due to uterine atony. - **Oxytocin** is a peptide hormone that stimulates uterine smooth muscle contraction by acting as an agonist at the oxytocin receptor. It is considered the first-line agent for restoring uterine tone and preventing or treating PPH. - **Methylergonovine** is an ergot alkaloid that acts primarily as an agonist at serotonin and alpha-adrenergic receptors on uterine smooth muscle, causing sustained contractions. It serves as a second-line agent when oxytocin alone is insufficient but carries risks such as hypertension and vasoconstriction. - **Carboprost** is a synthetic prostaglandin F2α analog that induces myometrial contractions via prostaglandin F receptor activation; it also serves as a second-line agent for refractory cases but may cause bronchospasm or gastrointestinal side effects. The combination may be used sequentially or together in severe cases of PPH unresponsive to monotherapy, with each drug targeting different pathways to maximize efficacy in restoring uterine tone[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxytocin + methylergonovine + carboprost.